New GLP-1 pill delivers up to 12% weight loss in 36 weeks
An experimental GLP-1 pill helped people with obesity or overweight lose as much as 12.1% of their body weight in just 36 weeks. Unlike injectable drugs such as Wegovy and Ozempic, aleniglipron is a small molecule that c
In a clinical setting, researchers studied the efficacy of aleniglipron, a novel GLP-1 pill, in weight loss. The study focused on individuals with obesity or overweight, as these patients often benefit from GLP-1 receptor agonists. The experimental treatment was compared to existing injectable drugs like Wegovy and Ozempic, which require more complex administration and storage procedures. The researchers aimed to investigate the safety and efficacy of aleniglipron in a real-world setting. The study's findings suggest that aleniglipron can lead to significant weight loss in a relatively short period. The results also imply that aleniglipron may be a more convenient and accessible option for weight loss management. However, it is essential to note that this study was not designed to provide definitive evidence for the long-term effects of aleniglipron or to establish its safety profile in all populations. Further research is needed to fully understand the potential benefits and risks of this treatment. The study's results should not be interpreted as a recommendation for the use of aleniglipron in clinical practice. Researchers should exercise caution when considering the application of this treatment in their own studies or clinical settings.